Lewsiville, TX, May 1, 2013
med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health will be introducing the first of Theranostics Health’s TheraLink™ Assays for use in patients with malignant diseases at the upcoming American Society of Clinical Oncology (ASCO) Annual ’13 Meeting, held in Chicago, IL from May 30, 2013 through June 4, 2013.
TheraLink HER Family Assay – Press Release
ASCO Annual Meeting
Exhibit Hall – Booth 2056
McCormick Place, Chicago, IL
May 31 2013 to Jun 4 2013
Gaithersburg, MD, August 17, 2012. Theranostics Health, Inc., a privately-held biotechnology company seeking to develop proteomic-based personalized medicine technologies, announced today that Dr. Glenn Hoke (President and Chief Executive Office) will be presenting at the Emerging Growth track at the 2012 Mid-Atlantic BIO Conference in Bethesda, MD. Dr. Hoke will be providing an overview to potential investors into Theranostics Health’s scientific and business development efforts to commercialize Theranostics’ TheraLink™ Assays for use in patients with malignant diseases.
Mid-Atlantic BIO Investor Presentations
Lewsiville, TX, August 15, 2012
med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics’ TheraLink™ Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments.
med fusion Partners with Theranostics Health
Rockville, MD. june 6, 2012.
Theranostics Health Inc. announced today that the U.S. Patent and Trademark Office issued Patent Number 8,168,568 B1 entitled: “Combinatorial Therapy for Protein Signaling Diseases” on May 1, 2012. This patent is exclusively licensed to Theranostics Health from the Public Health Service. The claims of the patent cover methods for selecting combination therapies based upon the activation status of disease or cancer-related protein pathways, and will be the basis for a series of TheraLink™ Diagnostic Assays under development which will provide a proteomic-based approach to personalized medicine.
Press Release – Theranostics Health Combination Therapy Patent